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Background: Aberrational epigenetic marks are believed to play a major role in establishing the abnormal features
of cancer cells. Rational use and development of drugs aimed at epigenetic processes requires an understanding
of the range, extent, and roles of epigenetic reprogramming in cancer cells. Using ChIP-chip and MeDIP-chip
approaches, we localized well-established and prevalent epigenetic marks (H3K27me3, H3K4me3, H3K9me3, DNA
methylation) on a genome scale in several lines of putative glioma stem cells (brain tumor stem cells, BTSCs) and,
for comparison, normal human fetal neural stem cells (fNSCs).
Results: We determined a substantial “core” set of promoters possessing each mark in every surveyed BTSC cell
type, which largely overlapped the corresponding fNSC sets. However, there was substantial diversity among cell
types in mark localization. We observed large differences among cell types in total number of H3K9me3+ positive
promoters and peaks and in broad modifications (defined as >50 kb peak length) for H3K27me3 and, to a lesser
extent, H3K9me3. We verified that a change in a broad modification affected gene expression of CACNG7. We
detected large numbers of bivalent promoters, but most bivalent promoters did not display direct overlap of
contrasting epigenetic marks, but rather occupied nearby regions of the proximal promoter. There were significant
differences in the sets of promoters bearing bivalent marks in the different cell types and few consistent differences
between fNSCs and BTSCs.
Conclusions: Overall, our “core set” data establishes sets of potential therapeutic targets, but the diversity in sets of
sites and broad modifications among cell types underscores the need to carefully consider BTSC subtype variation
in epigenetic therapy. Our results point toward substantial differences among cell types in the activity of the
production/maintenance systems for H3K9me3 and for broad regions of modification (H3K27me3 or H3K9me3).
Finally, the unexpected diversity in bivalent promoter sets among these multipotent cells indicates that bivalent
promoters may play complex roles in the overall biology of these cells. These results provide key information for
forming the basis for future rational drug therapy aimed at epigenetic processes in these cells.
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It is well-established that epigenetic marks are altered in
cancer cells (e.g [1]). These alterations may play impor-
tant roles in cancer [2,3]. Different cancers appear to
have different patterns of epigenetic changes. Impor-
tantly, drugs aimed at epigenetic processes are currently
used for clinical treatment of cancer [3,4]. Understan-
ding the specific actions of these drugs and the genomic
loci of their action may lead to future treatments that
are more specific. Currently, there is intense work on
developing new drugs aimed at epigenetic processes for
cancer treatment and gaining a more detailed under-
standing of the specific steps involved in the action of
these drugs on cancer cells. The efficacy of these drugs
may rely, in part, upon the specific spectrum of epi-
genetic changes in the cancer cells and specific patterns
of epigenetic changes may produce differential drug
sensitivity among patients [3]. Hence, gaining a better
understanding of epigenetic changes in different types of
cancer cells is critical.
Glioblastoma multiforme is a deadly cancer under in-
tensive investigation on a genomic level as part of the
The Cancer Genome Atlas (TCGA) project [5]. In this
cancer, it is believed that a specific population of cells -
brain tumor stem cells (“BTSCs”) - plays a crucial role
in the tumors. It has been proposed that targeting these
cells may be essential for successful treatment of this
cancer [6,7].
Several previous findings point toward the need for sys-
tematic investigation of DNA methylation and the three
histone marks H3K27me3, H3K9me3, and H3K4me3 in
BTSCs. Changes in DNA methylation have been widely
reported in cancer cells, are believed to play a major role
in cancer cell behavior, and are the target of current drug
and diagnostic marker development efforts [8]. Further-
more, changes in DNA methylation appear to be im-
portant in differentiation, including neural lineage cell
differentiation [9]. Finally, in some BTSCs, the BMP dif-
ferentiation pathway is silenced by aberrational methyla-
tion of the BMPRB1 gene promoter, producing resistance
to differentiation for these cells [10]. Hence, under-
standing DNA methylation patterns is critical. Similarly,
H3K27me3 is important to investigate because it has
repeatedly been shown to be an powerful repressive
epigenetic mark in promoters, the underlying enzymes
controlling this mark are known to be dysregulated or
mutated in many cancers [11], and changes in the dis-
tribution of this mark are important in differentiation of
neural stem cells [12]. In some BTSCs, EZH2, a key mem-
ber of the PRC2 complex that mediates the production of
H3K27me3 marks, is upregulated and plays a pivotal role
in glioblastoma tumor growth [13]. H3K4me3 is impor-
tant as a marker of open chromatin [14], has also been
shown to change in localization during differentiation[15], and is strongly correlated with gene expression [16],
and hence was also a target of this study. Finally,
H3K9me3 is prevalent but shows a very divergent lo-
calization to H3K27me3 [16] and is well known as an im-
portant component of lengthy regions of heterochromatin
in some cases [17]. In sum, these results strongly suggest
pivotal roles for these epigenetic marks in BTSCs.
Here, we performed a preliminary survey of these epi-
genetic marks in four lines of brain tumor stem cells.
These four lines have been shown to be multipotent [18].
We wished to compare our results to normal neural stem
cells, which may be the cell type of origin for BTSCs [19].
To model this normal population, we used normal fetal
human neural stem cells, which robustly grow under
typical cell culture conditions. We employed chromatin
immunoprecipitation applied to microarrays (ChIP-chip)
and methylated DNA immunoprecipitation applied to mi-
croarrays (MeDIP-chip) technologies.
We investigated three fundamental manifestations
[16,20] of these four epigenetic marks. Best known are
“focal peaks”, localized regions of epigenetic modification.
Abundant evidence supports the key role of these mo-
difications in transcriptional regulation when present in
proximal promoters [21]. Less studied, but prevalent in
the human genome, are long regions continuously posses-
sing a epigenetic modification (“broad modifications”,
[16,22]). We operationally define a peak as a broad modifi-
cation if it is >50 kb in extent. Many lengthy heterochro-
matic regions possess these long regions of H3K27me3 or
H3K9me3 [16]. Finally, we also investigated bivalent pro-
moters, which are promoters possessing two “opposing”
epigenetic marks, usually H3K4me3 and H3K27me3[20].
These bivalent promoters may play a key role in produ-
cing or maintaining fundamental stem cell properties [15].
Hence we investigated their distribution in BTSCs.
We addressed the following specific questions in this
study. How similar are the BTSCs from an epigenetic
mark perspective? How do BTSCs and neural stem cells
differ in epigenetic mark localization across the genome?
Do we observe differences in broad modifications among
BTSC types and neural stem cells? How different are the
collections of bivalent promoters among the BTSC types
and fNSCs?
We began by determining a set of promoters that pos-
sess each mark in every BTSC type (“core set”). This
core set was a substantial proportion of the total set of
promoters bearing a given mark for each BTSC, indi-
cating a significant core set but also significant epige-
netic diversity among BTSCs. For each epigenetic mark,
nearly all the core set was found in the corresponding
fNSC set, indicating great commonalities between fNSCs
and the common BTSC set of epigenetic mark localiza-
tions. However, fNSCs and BTSCs, when compared in a
pairwise manner, revealed large differences. Therefore,
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etic mark, individual cell types have many other sites
that are not shared with all the rest of the group. The
total number of H3K9me3+ promoters varied markedly
among some cell types, indicating differences in the ac-
tivity of the H3K9me3 production/maintenance system
among cell types. This system may present possibilities
for therapeutic intervention in some groups of patients.
We found that “broad modifications”, large areas of ge-
nomic space possessing an epigenetic mark (opera-
tionally defined as peaks >50 kb), also showed marked
differences in presence or extent among cell types. We
demonstrated that these differences were transcriptio-
nally relevant. Given that the mechanisms producing
these broad regions are significantly different than those
producing focal peaks, this system may also present
therapeutic possibilities. Finally, we surprisingly found
that the collection of bivalent promoters also differs
greatly by BTSC type, even though all our cell types
were multipotent [18]. Only a small number of bivalent
promoters were common to all five cell types. These ob-
servations suggest that bivalent promoter roles should
be further investigated in these cells. In total, our results
provide first steps toward understanding the epigenome
of these cells and indicate that successful targeting of
BTSCs using epigenome-aimed drugs may require care-
ful patient-by-patient analyses.
Results
ChIP-chip and MeDIP-chip in BTSCs and fNSCs
To investigate the distribution of epigenetic marks, we
used the 2.1 million probe NimbleGen HD2 microarray,
a design centered around promoter regions, most of
which are 10 kb in extent with 7 kb upstream and 3 kb
downstream of the transcription start site and 100 bp
probe spacing. In addition, this array design also in-
cludes a set of large tiled regions (the 44 ENCODE
regions; for full array description, see Methods). We per-
formed typical ChIP-chip and MeDIP-chip protocols
(see Methods). We produced single microarray experi-
ments for our twenty conditions (five cell types x four
epigenetic marks).
We used several approaches to validate our microarray
data. We started with the classical approach of exami-
ning known sites of modification (positive control sites)
in our microarray data (Additional file 1: Figures S1-S5).
Examination of this data for each mark revealed not just
consistent presence of the expected epigenetic mark, but
also that the waveforms were very similar across differ-
ent cell types. This suggests that technical noise was
quite low. In addition, we compared our data to public
ENCODE consortium data for these same regions [21].
This ENCODE ChIP-seq data and methylation data from
other cell types also closely matched the waveforms andlocation of our signals. This is consistent with reliable
signals across experiments.
We next sought to examine this issue on a global scale.
We examined promoters as to enrichment for different
marks by using the maxfour methodology (see Methods).
These analyses have been previously used [23,24]. Exam-
ples are displayed in Additional file 1: Figure S6. To begin,
we expect that when a promoter in one cell type has a
strong signal for H3K27me3, then that promoter will most
often display a strong signal in a second, closely related
cell type. Due to cell type differences, there will be some
promoters violating this pattern. In Additional file 1:
Figure S6A, we demonstrate that the enrichment values
for H3K27me3 are well-correlated between B73 cells and
fNSCs, with some clear sites showing cell-type specificity.
In contrast, as expected, few promoters have both high
H3K9me3 and H3K27me3 values (Additional file 1: Figure
S6B). Similarly, few promoters have both high H3K4me3
and H3K27me3 signals (Additional file 1: Figure S6C).
These graphs closely resemble previous published results
and closely match expectations from previous studies
[23,24]. Finally, we used the following logic. In a set of dis-
tinct, but closely related cell types, we expect that many
positive sites that show variability between cell types will
still be found in at least two cell types. We found that the
great majority of promoters showing a signal for an
epigenetic mark (“positive promoters” for that mark; de-
scribed in detail below) were found in at least two cell
types and a large number were found in all four BTSC
types (Additional file 1: Figure S7A). In contrast, we
found that promoters positive in only one cell type were
rare, except for the case of H3K9me3 (discussed below)
(Additional file 1: Figure S7B).
Similar numbers of sites across cell types except in the
case of H3K9me3
We examined differences among cell types using two
different approaches for each epigenetic mark: total
number of positive sites (“peaks”) and total number of
proximal promoters possessing at least one peak (“posi-
tive promoters”). To determine the number of positive
sites (“peaks”), we used the full set of peaks supplied by
NimbleGen (“generous parameters”; see Methods). We
focused on proximal promoter regions because these re-
gions are key for epigenetic transcriptional regulation.
Also, these regions are well-represented in this micro-
array design. To study these regions, we took positive
sites (“peaks”) and mapped them to an existing Nimble-
gen proximal promoter array design in which the tiled
region for promoters is designed to span the transcrip-
tion start site (typically 3.5 kb upstream and 750 bp
downstream; see METHODS). Then, we could score
each promoter as positive for a given mark or negative
based on presence of a peak in this proximal promoter.
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dataset unless otherwise noted. We also repeated our
basic analyses (e.g. generation of positive promoters for
each cell type) using a more stringent peak selection cri-
terion (FDR < 0.2; see METHODS for further details and
data files).
The results of these analyses are displayed in Figure 1.
These analyses revealed one striking result and one more
minor observation. For H3K9me3, there were large dif-
ferences in number of sites and number of positive pro-
moters across cell types, with the B12 line and fNSCs
having many more positive promoters than B25 cells
(>2× difference). Second, a more minor observation con-
cerns the relative number of H3K4me3 and H3K27me3
peaks vs positive promoters. There were more H3K4me3
positive promoters than H3K27me3 positive promoters,
as opposed to the total peak analysis. This result implies
that a large proportion of H3K27me3 peaks were found
outside of proximal promoter regions or that there was
a greater number of H3K27me3 peaks per promoter.
We found the H3K9me3 difference between B25 and
B12 cells surprising because our close examination of some
known sites (Figure 2, Additional file 1: Figures S3,S4) did
not demonstrate any obvious differences. The B25 peak
waveforms and amplitudes at these control sites did not
differ from those of the other cell types in this study.Figure 1 Number of peaks and peak-containing promoters for each c
epigenetic mark per cell type. This analysis used generous parameters lead
promoters possessing each epigenetic mark. Peaks were mapped to proxim
promoter, the promoter was scored as positive (see RESULTS and METHOD
H3K9me3+ promoters.Therefore, we employed two additional global analysis
approaches. First, analysis of only high confidence peaks
(FDR < 0.2; see Methods for additional description) also
yielded large differences between B12 cells and B25 cells in
both total number of peaks and total number of positive
promoters for H3K9me3 (Additional file 1: Figure S8).
Hence, the observed differences cannot be attributed to
the use of generous parameters. Second, we used the
maxfour approach (maxfour; see [23] and Methods) be-
ginning with quantile normalized and smoothed data to
examine this conclusion. This method predicted the same
rank order as the NimbleGen analyses in number of posi-
tive promoters (i.e. fNSC > B12 > B73 > B48 > B25). Fur-
thermore, examination of the distribution of maxfour
values revealed a strong positive shift in the B12 distribu-
tion as compared to that of B25 cells, indicating that many
more promoters had higher H3K9me3 signals in B12 cells
(data not shown). Therefore, use of two different analysis
approaches using two different data preprocessing me-
thods (none for NimbleGen, quantile normalization +
smoothing for maxfour), and varying parameters for the
NimbleGen peak determination, yielded qualitatively simi-
lar conclusions. This large difference in H3K9me3 positive
promoter counts among these cells points toward a sig-
nificantly altered H3K9me3 system for some types of
BTSCs as compared to fNSCs.ell type and epigenetic mark. A. Number of peaks found per
ing to relatively large numbers of potential peaks. B. Number of
al promoter regions; if a peak (or multiple peaks) overlaps a

















































Figure 2 Universe of promoters that possess each epigenetic mark. A. Examples of each epigenetic mark for a single promoter from each
BTSC type. Note great similarity in waveforms across cell types for a given epigenetic mark. Left axis is log2 enrichment ratio. For genomic
location (top axis), only single coordinate is shown; genomic distance between tick marks is (panels from left to right): 1 kb, 6 kb, 4 kb, 8 kb. All
displayed transcripts extend beyond edge of figure area. B. Diagram of number of promoters that possess a given epigenetic mark in at least
one type of BTSC (“universe” set; number in parentheses) and the number that possess it in every BTSC type (“core” set). Number in core set:
H3K4me3: 6742; H3K9me3: 1650; H3K27me3: 3198; meC: 5360. See RESULTS and METHODS for details of computation of sets.
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Mark Locations
Epigenetic marks are controllers of gene transcription and
hence play an essential role in establishing cellular
identity. Different types of cells can be distinguished by
comparing epigenetic mark distributions and these distri-
butions can even be used to predict relatedness of cell
types [25]. We sought to address the issue of epigenetic
similarities and differences among BTSCs. We used the
promoter-centric analysis because marks in proximal
promoter sites are crucial for transcriptional control. Fur-
thermore, this analysis approach eliminates some me-
thodological noise concerns (see Methods). Additionally,
we validated qualitative results using a different analysismethod (rank analysis as in [25]; data not shown). For
each epigenetic mark, we computed two different basic
sets. First, we computed a “core” set of positive promoters
for each mark that are present in every BTSC (Additional
files 2, 3, 4 and 5). These core sets probably contain epi-
genetic modification sites that produce the BTSC pheno-
type. Second, to gain an idea of the total variability in
locations among cell types for a given epigenetic mark, we
also computed a “universe” set that includes every pro-
moter that is positive for a given epigenetic mark, whether
in only one type of BTSC, or in two, three, or all four
types (Additional files 6, 7, 8, and 9).
To interpret this data, we employed the following logic
for each epigenetic mark. If different BTSCs share most
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large fraction of the universe set. Conversely, if there are
fewer shared positive promoters, then the core set will
be a small fraction of the universe set, because most
positive promoters will not be present in all four cell
types.
Analysis of this data yielded several conclusions. First,
there was a substantial core set of positive promoters for
each epigenetic mark (H3K4me3: 6742; H3K9me3: 1650;
H3K27me3: 3198; meC: 5360). Second, this core set,
although large, was less than half of the universe set in
each case (Figure 2). We were concerned that the rela-
tive size of the core set would be greatly reduced if there
were a single “outlier” cell type that shared few sites with
the other cell types. To investigate this possibility, we
performed a more detailed analysis categorizing each site
as belonging to either exactly one, two, three or all four
types of BTSCs (Additional file 1: Figure S7). These
results, in conjunction with detailed analysis of the com-
position of sites found in the “only present in one type”
set, indicated that no single cell type was strongly
biasing results. Overall, these results establish a large
core set for each epigenetic mark that will be useful for
further functional understanding of the general features
of the BTSC phenotype. However, these results also
demonstrate significant differences in the epigenetic
landscape among BTSCs.
We performed gene ontology analysis using the DAVID
server [26] for each of the core sets (full results in
Additional files 10, 11, 12, and 13). For H3K4me3, we
found enrichment of a large number of categories, with
prominent enrichment in general gene ontology terms
(e.g. “cytosol”). Notably, other terms potentially related to
cancer also showed enrichment such as “GO: 0006974 ~
response to DNA damage stimulus” and “GO: 0007049 ~
cell cycle”. For H3K9me3, we found prominent enrichment
of the cell adhesion and zinc-finger gene categories
(INTERPRO Cadherin term, zinc finger regions (UP_SEQ_
FEATUREs), and consistent gene ontology categories
for these (GO: 0007156 ~ homophilic cell adhesion,
GO: 0003677 ~DNA binding)). For H3K27me3, analysis
revealed enrichment of categories related to cell surface
receptors, in particular G-protein coupled receptors
and ion channels. Finally, for methylated DNA, analysis
showed marked enrichment in categories related to tran-
scriptional regulation and DNA binding categories. In
sum, these results imply a complicated scenario in which
there is potentially prominent and pan-BTSC repression
of various transcriptional regulation genes (via H3K9me3
or DNA methylation) and cell surface molecules (some re-
ceptors via H3K27me3+ and some cell adhesion genes via
H3K9me3), along with activation of various genes poten-
tially linked to the cancer phenotype (via H3K4me3; e.g.
cell cycle genes). Further exploration of these topics willprobably require extensive experimentation, including
large scale gene expression data.
Epigenetic differences among fNSCs and BTSCs
There is significant evidence that neural stem cells may
be the cell-type of origin for BTSCs [6,7,19]. We sought
to determine changes in epigenetic mark locations in-
duced by the putative transformation of neural stem
cells (which we modeled with fNSCs) to BTSCs. We rea-
soned that these epigenetic alterations may give insight
into (1) key sites of epigenetic marks that produce or
contribute to the cancerous BTSC phenotype or (2) may
provide avenues for therapeutic intervention, even if
these new sites do not directly produce the cancer
phenotype. These analyses rely on the assumption that
human fNSCs are a good model for the epigenetic marks
of the normal cell-type of origin for our BTSCs.
We are interested in two basic set of changes (Figure 3).
First, we examine which epigenetic marks at which pro-
moters are changed in every BTSC as compared to fNSCs.
This conservative set may point toward key sites and po-
tentially provide mechanistic insights into this repro-
gramming. Second, we examine which epigenetic marks
are changed in at least one type of BTSC as compared to
fNSCs. This larger set may point toward a set of pro-
moters than can be epigenetically reprogrammed in the
cancer process and, via overall analysis, may give insight
into underlying mechanisms or molecular components of
this large-scale reprogramming. On a technical level, this
set is also important for derivation of changes that occur
in comparing fNSCs to every BTSC (see below and
Figure 3).
We were particularly interested in alterations found in
every BTSC vs fNSCs. Full datasets are present in
Additional files 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
and 25. As shown in Figure 3A, these changes could
be gain of an epigenetic mark in every type of BTSC
(Figure 3Aleft) or loss of an epigenetic mark in every
type of BTSC (Figure 3Aright). To derive these changes,
we examined differences among the fNSC set and the
universe and core sets of BTSC promoters for each epi-
genetic mark (logic is displayed in Figure 3B).
This analysis revealed a relatively small set of changes
that occurred in every BTSC vs. fNSCs (Figure 3C). For
H3K4me3, H3K27me3 and meC, the number of pro-
moters that lost the marks (in the putative neural stem
cell - > BTSC process) significantly outweighed the num-
ber of promoters that gained the marks (quantitation in
Figure 3C). For H3K9me3, the difference was very large
(1412 lost vs 70 gained). The large number of H3K9me3
locations that are lost and the small number gained may
be due to the small size of the core H3K9me3+ pro-
moter set (Figure 2B). The small core set size is partially
caused by large differences among BTSC types in
3em72K3H3em4K3H
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1: unique to fNSCs (not in any 
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Figure 3 Comparison of fNSCs and BTSCs. Human fetal neural stem cells were used as model for the normal precursor cells for BTSCs.
A. (left) Example of gain of H3K4me3 mark in a promoter in all four BTSC lines, as compared to fNSCs. (right) Example of loss of H3K27me3
mark in all four BTSC lines, as compared to fNSCs. Left axis is log2 enrichment ratio. All displayed transcripts extend beyond edge of figure area.
B. Explication of comparison of fNSC promoter sets to BTSC promoter sets by epigenetic mark. “Universe” and “core” sets as in Figure 2. fNSC is
left circle in each case. Critical computations in diagram are indicated in bold, italic, underlined font. C. Results of comparison of fNSC and
universe or core BTSC sets for each epigenetic mark.
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above (Figure 1, Additional file 1: Figure S7).
Inspection of the universe set results indicated that,
overall, thousands of promoters can be reprogrammed
in the putative NSC - > BTSC transformation for each
epigenetic mark.We examined the composition of the group of con-
sistent precursor cell (fNSC as model) to BTSC changes
(changed in every BTSC cell) for each epigenetic mark
using the DAVID server (full data in Additional files 26,
27, 28, 29, 30, 31, 32 and 33). We separately analyzed sets
of gains and losses. Gene ontology analysis revealed only a
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BTSCs gained this mark for zinc finger genes. For
H3K27me3, BTSCs gained this mark for receptors, es-
pecially G-protein coupled receptors, and lost this mark
in the categories of embryonic limb morphogenesis and
skeletal development. For DNA methylation, there were
clear gains in genes related to the general categories of
transcription and development and clear losses in genes
in the categories of receptors and the general category
of membrane. Overall, these results point toward a com-
plex picture in which potentially some zinc finger genes
gain repression (via gain of H3K9me3), some receptors
are newly repressed (via gain of H3K27me3+) and other
receptors are potentially activated (via loss of DNA
methylation), and genes related to transcription are also
potentially repressed (via gain of DNA methylation) and
some developmental genes are activated (via loss of
H3K27me3+) and some repressed (via gain of DNA
methylation). The core data sets themselves have a
biased gene ontology category composition, so these
results are in part due to core set composition effects.
Further experimental investigation of BTSCs will be





















Figure 4 Examples of variation among cell types in the extent of bro
Note the large differences between B73 and B12 in particular. Left axis is lo
indicates differential region, which encompasses transcription start site for
Note particularly large difference between B73 and fNSC. Markings for “Tran
the + strand (i.e. TSS (transcription start site) on left side of box), while boxe
strand (i.e. TSS is on right of box).Regions of Broad Modification Vary Among Cell Types
We use the term “broad modification” to denote long re-
gions of chromosomal space in which there is a given
epigenetic modification present continuously (>50 kb),
as opposed to focal regions of modification (“peaks”) in
a promoter or other region. These broad modifications
are prevalent in the human genome [16]. The mecha-
nisms that create broad modifications are believed to be
significantly different from those that create focal modi-
fications [22]. Hence, variations among cell types in this
type of modification implicates mechanisms different
than those involved in focal peak dynamics. Here, we
examine variation in broad modifications among our five
cell types.
To study alterations in broad modifications, we exam-
ined the longer regions represented in this microarray for-
mat (see Methods; Additional file 34). Strikingly, cell type
differences were found in 26 of 44 regions for H3K27me3
(e.g. Figure 4). In contrast, clear changes in broad mo-
difications were much less prevalent for H3K9me3 (4
of 44) and were absent for meC and H3K4me3 (0 of 44 in
each case). These results imply frequent dysregulation of



















ad regions of H3K27me3. A. HOXC cluster region of chromosome 12.
g2 enrichment ratio. B. Region of chromosome 6. Large arrow
FOXP4 gene (gene indicated by smaller arrow in Transcripts track).
scripts” tracks: boxes above the line indicate transcripts that are on
s below the line represent transcripts that are from the opposite
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array format with respect to investigating broad modifica-
tions, conclusions around these results must be tentative.
We next examined whether broad region variation
among cell types was relevant to transcriptional regu-
lation. The chr19: 59023585 - 60024460 region encom-
passes the CACNG7 gene (Figure 5A). This gene has been
recently described as being routinely downregulated in
BTSCs as compared to normal neural stem cells [27]. In
this region, we found a broad modification (H3K9me3+)
in B73 cells but not in B12 cells. This broad modification
was restricted to H3K9me3 and was not present with
H3K27me3 in this region (Figure 5B). We examined
mRNA levels of CACNG7 using quantitative PCR and
found that B12 cells had higher levels than B73 cells
(Figure 5C). This difference was very large (>1500 fold
















































































Figure 5 Differential presence of a broad region of H3K9me3 affects
region of H3K9me3 that is missing in other cell types (large arrow). Small a
this CACNG7 region reveals H3K9me3 presence in B73 cells but not B12 cel
C. Quantitative PCR of mRNA abundance (cDNA) demonstrates that B12 ce
(mean + standard deviation) are expressed as fraction of the GAPDH level;
using ACTB as a control (see RESULTS).Hence, the change in the presence of this broad region of
H3K9me3 is correlated with a large difference in mRNA
levels for CACNG7, suggesting that these changes in
broad modifications can have transcriptional, and presu-
mably ultimately functional, consequences.Bivalent Promoters
“Bivalent promoters” are promoters that possess two
“opposing” epigenetic marks, most commonly H3K4me3
in combination with H3K27me3 [28]. This class of pro-
moters is prominent in stem cells and is believed to
contribute significantly to the multipotent nature of tis-
sue-specific stem cells [29]. We surveyed bivalent pro-
moters in BTSCs and sought to determine whether there
were regular patterns of differences among fNSCs and
















transcription. A. H3K9me3 ChIP-chip results. B73 cells show broad
rrow (Transcripts track) indicates CACNG7 transcript. B. Detailed view of
ls. H3K27me3 is not present in either B73 or B12 cells in this region.
lls contain much higher levels of CACNG7 than B73 cells. Values
t-test revealed p < 0.005 for this difference. Similar values were seen
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mal precursor cells of BTSCs.
We used a conservative selection strategy to find pro-
ximal promoters that showed clear evidence of strong pre-
sence of two epigenetic marks (H3K4me3+/H3K27me3+
(“K4/K27 bivalent promoters”) or H3K4me3+/H3K9me3+
(“K4/K9 bivalent promoters”); see Methods for details)
in a single promoter. Detailed lists are presented in
Additional files 35, 36, 37, 38, 39, 40, 41, 42, 43 and 44.
Visual inspection of a random subset of these bivalent
promoters showed that, qualitatively, in the majority of
cases, the epigenetic marks seemed to occupy different re-
gions of the promoter (Figure 6A, B(left)). Hence, direct,
clear overlap of marks for the same probes was observed
infrequently (Figure 6B(right)). To quantify this obser-
vation, we performed a preliminary analysis of bivalent
promoters in B73 cells. We analyzed each K4/K27 or
K4/K9 promoter to determine if the peaks were overlap-
ping or separate. We found that 37% (399 of 1083 ana-
lyzed) K4/K27 promoters and 40% (147 of 368 analyzed)
of K4/K9 promoters had non-overlapping peaks (see
Methods for analysis). Our analysis method will underesti-
mate the fraction of non-overlapping histone modifica-
tions because peak widths are larger than the actual
underlying chromatin modification. This is due to the size
of chromatin fragments used in ChIP experiments. This
situation produces apparent overlap when the underlying
modifications are separated in genomic space. Nonethe-
less, these results support the existence of a major popula-
tion of bivalent promoters with non-overlapping histone
modifications. Modeling the relationship of underlying
modification to peak morphology may allow better quanti-
fication in the future.
We began by analyzing K4/K27 bivalent promoters.
We found that the number varied considerably among
cell lines ranging from 898 in B25 cells to 2301 in fNSCs
(Figure 6C). Analysis of bivalent promoter changes from
fNSCs to any single type of BTSC demonstrated large
alterations and substantial diversity among patterns in
different cell types. There were few bivalent promoters
found in all 5 cell types (5% of fNSC total; 113/2301)
and fewer that went from bivalent in fNSCs to losing
both marks in all BTSCs (going to K4-/K27- status) (1%;
26/2301). These results point toward notable diversity in
K4/K27 bivalent promoters for each cell type.
We performed similar analyses with bivalent K4/K9
promoters. We found that the number of K4/K9 bivalent
promoters also varied substantially among cell lines
(Figure 6C(right)). Comparison of the fNSC set to sets
from individual BTSC types revealed substantial overlap.
However, there was only a small set of bivalent promoters
found in all BTSCs and fNSCs, and fewer still that lost
both marks in all BTSCs (going to K4-/K9-) as compared
to fNSCs (Figure 6C). These results indicate considerabledifferences between each cell type in the set of K4/K9
bivalent promoters.
We were particularly interested in epigenetic differences
between fNSCs and BTSCs at these bivalent promoters,
because loss of bivalency is often considered an important
step in differentiation. Alterations from K4+/K27+ to only
K4+ would poise a promoter for activation (Figure 6D
(right)). We found 137 promoters that went from
K4+/K27+ in fNSCs to only K4+ in all BTSCs. Gene
ontology analysis of the associated genes yielded mostly
general categories except for categories linked to tran-
scription (GO:0006355 ~ regulation of transcription, DNA-
dependent) and proto-oncogenes (SP_PIR_KEYWORDS
“Proto-oncogene” category).
In contrast, alterations from K4+/K27+ to solely K27+
would place a promoter in a repressive state (Figure 6D
(left)). We found 191 promoters that went from K4+/
K27+ in fNSCs to only K27+ in all BTSCs. Gene onto-
logy analysis of the associated genes yielded categories
(SP_PIR_KEYWORDS) linked to ion channels (“ionic
channel”, “ion transport”, “voltage-gated channel”), but
no statistically significant gene ontology categories.
Similar logic holds for K4+/K9+ promoters. We found
99 promoters that went from K4+/K9+ in fNSCs to only
K4+ in all BTSCs. Gene ontology analysis of the asso-
ciated genes yielded categories (SP_PIR_KEYWORDS)
linked to transcription (“transcription”, “transcription
regulation”) and “mental retardation”, but no statistically
significant gene ontology consortium categories.
We found 22 promoters that went from K4+/K9+ in
fNSCs to only K9+ in all BTSCs. Gene ontology analysis
of the associated genes yielded a number of categories
linked to cell adhesion, including GO:0016337 ~ cell-cell
adhesion.
Taken together, these analyses point toward potential
activation of genes linked to transcription and proto-
oncogenes due to loss of the repressive mark (i.e. loss of
either H3K27me3+ or H3K9me3+) and potential repres-
sion of genes linked to cell adhesion (K4+/K9+ to K9+)
and ion channels (K4+/K27+ to K27+). Again, these re-
sults are in part related to the composition of the core
sets for each epigenetic mark (see above analysis of
DAVID results for core sets).
Full DAVID results are presented in Additional files
45, 46, 47, 48, 49, 50 and 51. Other bivalent promoter
analyses are presented in Additional files 52, 53, 54, 55,
56 and 57.
Discussion
In this report, we surveyed four well-studied epigenetic
marks using ChIP-chip/MeDIP-chip in four brain tumor
cell lines and fetal neural stem cells. We used fetal
neural stem cells as a model for the normal cell type of













































































































Figure 6 Bivalent Promoters in fNSCs and BTSCs. A. H3K4me3+/H3K27me3+ promoter in fNSCs and B73 cells. Note that both marks are in the
proximal promoter but show little overlap. This was the most common pattern. Left axes are log2 enrichment ratio. B. Two patterns for H3K4me3
+/H3K9me3+ promoters (B12 cells). (left) Non-overlapping marks in proximal promoter. This is the most common pattern. (right) Overlapping marks.
Left axes are log2 enrichment ratio. C. (left) H3K4me3+/H3K27me3+ promoter counts in each cell line and the number shared with fNSCs. (right)
H3K4me3+/H3K9me3+ promoters in each cell line and number shared with fNSCs. ALL refers to bivalent promoters found in all 5 cell types. LOST
refers to promoters that are bivalent in fNSCs and lack both marks in every BTSC line. D. Examples of fNSC H3K4me3+/H3K27me3+ promoters that
resolve to either H3K27me3+ (left) or H3K4me3+ (right) promoters in the B73 line. Left axes are log2 enrichment ratio. Markings: For A, B, and D,
transcripts are shown with arrows and line drawing. All displayed transcripts extend beyond edges of panel in figure. Markings for top axes (genomic
coordinate of first tick mark (increment to next tick mark)): A: chr17:33,063,000 (3 kb); B: left: chr3:114,711,000 (1 kb); right: chr19:62,812,000 (1 kb); D: left:
chr9:23,790,000 (6 kb); right: chr9:68,541,000 (3 kb).
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lation) have been shown to play important roles in tran-
scriptional regulation and function of neural precursor
cells [30], the putative precursor cells for BTSCs [7,19].
Our primary goals were to identify similarities and dif-
ferences among the brain tumor stem cell lines and also
to understand potential epigenetic reprogramming from
neural stem cells to brain tumor stem cells. We surveyed
various epigenetic phenomena, including focal peaks,
areas of broad modification, and bivalent promoters. For
most of our analyses, we performed a promoter-centric
analysis by mapping peaks to proximal promoter re-
gions, where the presence of an epigenetic mark has a
great probability of affecting transcription [31]. Our
primary conclusions were as follows. (1) We identified a
“core set” of promoters possessing each epigenetic mark
in every surveyed BTSC cell type. However, different
BTSC lines showed large numbers of sites differing from
the core set for each epigenetic mark. (2) The core set
was largely found also in fNSCs, with only a small num-
ber of mark locations showing consistent changes from
fNSCs to BTSCs. However, for any single BTSC type vs.
fNSCs, there were relatively large numbers of differences
detected. (3) H3K9me3 showed robust and large differ-
ences among cell types in total number of positive pro-
moters and peaks, pointing toward differences in the
H3K9me3 producing or maintenance system among
these cell types. (4) We detected significant and clear
changes in broad modification areas for H3K27me3 and,
to a lesser extent, for H3K9me3, implying that the pro-
cesses creating or maintaining these broad modifications
differed in activity among cell types; in one case we veri-
fied that this change in a broad modification affected
gene expression. (5) We detected large numbers of bi-
valent promoters. Most bivalent promoters did not dis-
play direct overlap of epigenetic mark signals. Rather,
the opposing marks seemed to occupy nearby regions of
the proximal promoter. (6) There were considerable dif-
ferences in the sets of promoters bearing bivalent marks
in the different cell types and few consistent changes
from fNSCs to BTSCs.
A key result of this work was the determination of the
“core sets” - a set of promoters for each epigenetic mark
that have the epigenetic mark in every BTSC. Because
similar cell types show significant similarities in the sets
of promoters bearing a given epigenetic mark [25], the
existence of a significant core set was not surprising.
However, we also detected a large amount of variability
among the BTSCs; for each epigenetic mark, the core
set comprised well less than half of the total set (uni-
verse set) of positive promoters. Given previous gene
expression work, this variability among BTSCs is not
surprising. Gene expression analyses across glioblastoma
multiforme tumors taken in toto has shown that thereare significant subclasses of glioblastoma that differ in
large ways in gene expression patterns [27,32,33]. Fur-
thermore, gene expression data from a panel of BTSCs
(not including the ones used in this study) indicated sig-
nificant variability among the BTSCs in gene expression
patterns [34]. Finally, preliminary gene expression array
data from the BTSCs used in the study (G.Cairncross
and S.Weiss, unpublished observations) indicates that
the BTSCs used in this study vary significantly in gene
expression patterns.
Overall, gene expression studies across different types
of BTSCs and neural stem cells demonstrate large sets
of genes that are downregulated in one cell type versus
another and even in BTSCs as a class vs. neural stem
cells (e.g. [34,35]). A recent analysis [34] concluded that,
unlike our previous findings in liver cancer [23], copy
number changes explained only a small amount of va-
riation in gene expression between BTSCs and normal
neural stem cells and that therefore other mechanisms
must be important. Hence, the data in our study, in con-
junction with other results, can point toward the poten-
tial epigenetic basis of gene repression in these BTSCs.
This can be seen most clearly by a brief examination of
the recent results of Engström et al. (2012). TUSC3 is of
particular interest because Engström et al. (2012) estab-
lish that it is down regulated in glioblastoma cells as
compared to neural stem cells and this gene was part of
a key set of genes predicting survivability of patients. In
bulk glioblastoma tumor samples [36], which comprise
both BTSCs and non-BTSCs, this gene is repressed via
promoter DNA methylation. However, in our BTSC
samples, we find that H3K27me3 in the TUSC3 pro-
moter may be the major repressor. Similarly, TES levels
have been described as discriminating normal neural
stem cells from BTSCs [34]. This gene is downregulated
via promoter DNA methylation in bulk tumor samples
[37]. Again, in contrast, we detect strong H3K27me3
signals across BTSC types for this gene’s promoter
and little sign of promoter methylation, implying that
H3K27me3, not DNA methylation, is probably the re-
pressive mark. These results highlight the importance of
studying epigenetic marks directly in BTSCs as opposed
to solely tumor samples or other glioblastoma cell lines.
Rational targeting of gene expression in BTSCs using
drugs aimed at epigenetic processes obviously requires
understanding of the epigenetic marks that are affecting
gene expression specifically in the context of BTSCs,
which may differ from other glioblastoma cell types.
Comparison of the core set for each epigenetic mark
with the corresponding set for fNSCs revealed that the
core sets were almost entirely found in the correspon-
ding fNSC sets. This indicates that the core set is ba-
sically shared not only among the four BTSCs but also
fNSCs. However, comparison of the fNSC epigenetic
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ences. This may point toward individualized therapeutic
targets for patients with a given type of BTSC. Rational
drug treatment based on specific properties of a tumor,
perhaps even BTSCs derived from an individual tumor,
may become a relevant clinical possibility as personal-
ized medicine becomes a larger part of cancer therapy
and there is a greater understanding of the overall sys-
tems biology of different BTSCs and fNSCs.
Striking and robust differences were found among cell
types in the number of promoters bearing the H3K9me3
mark, which points toward different levels of activity of
the systems establishing and/or maintaining this mark in
these cell types. H3K9me3 appears to have complex ac-
tions in gene regulation [16], but clearly plays an import-
ant role in neural progenitor cells in producing sustained
inactivation of some genes and also plays a large role in
some heterochromatic regions [30,38]. We also noted dif-
ferences among cell types in large broad regions of modifi-
cation with H3K9me3. We establish the transcriptional
relevance of a difference in an H3K9me3+ broad mo-
dification in that it affected transcription of CACNG7.
CACNG7 has been described as being downregulated in
BTSCs vs normal neural stem cells [34]. These differences
among cell types, in particular among some of the BTSCs
and fNSCs, present the intriguing possibility that this
H3K9me3 system may be a relevant target for anti-BTSC
therapy.
We detected differences among cell types in broad
modification regions for H3K27me3 in many of the
more lengthy regions that were tiled in this array format.
Unfortunately, this array format only covers a portion of
the genome, hence, it will be necessary to use other
methods, most likely ChIP-seq, to fully establish the
prevalence of differences in broad modifications for this
mark across different cell types. However, our work pro-
vides compelling evidence that broad regions of mo-
dification should be a focus of future research, in that
regions may play important roles in shaping the biology
of these cells and may present therapeutic targets. Tar-
geting the mechanisms that produce these broad regions
of epigenetic change represents a potential frontier for
epigenetic targeted cancer therapies.
For all five cell types, bivalent promoters, in most
cases, had the two opposing epigenetic marks occupying
different portions of the proximal promoters, although
usually the marks were found directly adjacent to each
other. This presents a different picture than that usually
associated with bivalent promoters, in which the epigen-
etic mark signals actually overlap each other [29]. The
observation of adjacency has clear mechanistic implica-
tions. First, this observation implies that different his-
tone complexes would have each mark. In contrast, for
the case of overlapping opposing marks, the traditionalinterpretation is that both marks are (often) on the same
histone tail. In some cases, this has been directly been
shown to be so [20,29]. Our preliminary gene expression
results (G. Cairncross and S. Weiss, unpublished obser-
vations) indicate that, like the “overlapping” bivalent
promoters, these “non-overlapping” bivalent promoters
yield very low gene expression, particularly in the case of
H3K4me3+/H3K27me3+ bivalent promoters. We also
analyzed the case of H3K4me3+/H3K9me3+ bivalent
promoters. These bivalent promoters were rarer than
H3K4me3+/H3K27me3+ bivalent promoters. A portion
of the bivalent promoter set (either K4/K9 or K4/K27)
from any single BTSC type was shared with fNSCs but
there was only a small set of bivalent promoters that
were shared among all BTSCs and fNSCs.
The BTSCs in this study are multipotent [18], as are
fNSCs. Because bivalent promoters have been thought im-
portant for multipotency, we initially hypothesized that
the bivalent promoter set shared among all BTSCs and
fNSCs (the common set) would be relatively large in abso-
lute number and as a proportion of all bivalent promoters
in these cells. We can rationalize the relatively small com-
mon set and relatively large set of bivalent promoters for
each individual cell type in several ways. First, it is possible
that the cancerous nature of the BTSCs has produced
other genomic alterations that affect the bivalent pro-
moter system. Second, bivalent promoters may play im-
portant roles in allowing rapid committed cell production
but may not be essential for it [28]. Third, there may be
several different sets of bivalent promoters that can all
support multipotency. Fourth, bivalent promoters may be
less important for multipotency than previously thought.
Fifth, only a small conserved set of bivalent promoters
may be important for multipotency, while most bivalent
promoters have other or minor roles. Our common set of
bivalent promoters across cell types may include these
critical promoters. Sixth, differences in bivalent promoter
sets may, in part, produce biases toward production of dif-
ferent types of committed lineage cells. Differentiating
among these possibilities will require extensive further
investigation.
In general, the spectrum of similarities and differences
in sites of epigenetic marks shown in this study suggest
different programs of epigenetic change (versus neural
stem cells or other cell types of origin) for these different
BTSCs. In particular, given the growing evidence for the
dynamic nature of epigenetic marks at many sites and
the need for active maintenance of these marks at many
sites [39], these sets of differences may be actively main-
tained in each cell type. With this scenario, there may be
many points of intervention for possible therapeutic tar-
geting. Although gene ontology analyses of cell type dif-
ferences revealed some suggestive categories, there were
no striking findings of differences. Successful therapeutic
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tems biology view of these different cell types. While this
may seem a daunting prospect, the rapid advances in
high-throughput technologies, particularly in omics
fields, coupled with declining costs and higher quality
datasets can provide hope for this possibility.
Conclusions
In total, this work takes significant steps toward under-
standing the epigenetic marks in these BTSCs on a large
genomic scale. We establish a core set of promoters for
each epigenetic mark that bear the mark across every
BTSC. Our work also points toward mechanisms of re-
pression for genes in these cells, which is of particular
interest as BTSC gene expression profiles and patient
survival time are correlated [34]. We find substantial
differences among cell types in broad modifications and
bivalent promoters. These results indicate substantial
variation in activity of the production/maintenance sys-
tems for H3K9me3 and for broad regions of modifica-
tion (H3K27me3 or H3K9me3). Interestingly, bivalent
promoters often had the two opposing marks imme-
diately adjacent to each other in the proximal promoter
as opposed to having direct overlap. The large variability
among BTSCs may indicate that the systems biology of
these cells may vary greatly and that future epigenetic
therapies should be targeted toward subpopulations of
patients, or in the extreme, individual patients.
Methods
GBM BTSC and fNSC Cell Culture
All glioblastoma multiforme (GBM) BTSC and fNSC neu-
rosphere cell lines were kindly donated by Dr. Sam Weiss
and Dr. Greg Cairncross (University of Calgary, Calgary,
Alberta, Canada) [18]. The cell types referenced in this
manuscript use the same numbering scheme as those pre-
viously published [18], e.g. B25 in this manuscript is the
same cell line as “BT025” as referenced in [18]. Isolation
of fresh tumour samples and the establishment of BTSC
and fNSC neurosphere culture have been previously
described [18]. Initial, limited, characterization of these
cells [18] indicates that B12 cells have amplification of the
EGFR locus and that B73 cells possess p53 mutations. All
cells were cultured from tumors from male patients, aged
50-70, diagnosed with glioblastoma stage IV (Table S1 of
[18]). The GBM BTSCs and fNSC neurospheres were
maintained and expanded in serum-free NS media (Neu-
roCult NS-A media, StemCell Technologies, Cat: 05751)
supplemented with EGF (20 ng/mL, Peprotech, Cat: AF-
100-15), FGF (20 ng/mL, R&D Systems, Cat: 233-FB)
and heparin sulfate (2 μg/mL, StemCell Technologies,
Cat: 07980). BTSC and fNSC neurospheres were passaged
when the sphere reached an adequate size (200 ~ 400
microns). For cell passaging, the neurospheres weredissociated into single cells by treating with Accumax
(Innovative Cell Technologies, #AM105) for 10 min at
37°C and gently triturating using P200 pipettes (Gilson).
Cells were then counted and replated. When necessary,
cells were fed weekly by adding the supplementary factors
listed above (FGF 20 ng/mL, EGF 20 ng/mL, heparin
2 μg/mL).
Chromatin Immunoprecipitation Assay (ChIP), Methylated
DNA Immunoprecipitation Assay (MeDIP), ChIP-chip and
MeDIP-chip
Chromatin immunoprecipitation (ChIP) assays were per-
formed as previously described [23] with the following
modifications. Briefly, BTSC and fNSC neurospheres were
harvested and the spheres were dissociated into a single cell
suspension by treating them with Accumax (Innovative Cell
Technologies) for 10 min at 37°C followed by triturating
with P200 Pipettes. Dissociated BTSC and fNSC cells were
cross-linked with 1.0% (final concentration) formaldehyde
for 15 min. Nuclear extracts were prepared and sonicated.
We followed standard ChIP assay protocols (http://
farnham.genomecenter.ucdavis.edu/pdf/FarnhamLabChIP%
20Protocol.pdf). Methylated DNA immunoprecipitation
(MeDIP) assays used a selective 5-methylcytidine antibody
(Eurogentec, BI-MECY-0500; previous used in MeDIP-
chip [23,25]) and genomic DNA was extracted using
DNeasy Blood & Tissue Kit (QIAGEN). Extracted gen-
omic DNA was sonicated (Bioruptor Sonicator (Diage-
node)) to an average size of 600 bp, denatured at 95°C
for 10 min, and quickly chilled on ice prior to ChIP assay
using Staphylococcus aureus protein A-positive cells.
Antibodies used for the ChIP assays include H3me3K27
(rabbit polyclonal, 5.0 μg, Upstate 07-449; previous used
for ChIP-chip work in [23-25]), H3me3K4 (rabbit poly-
clonal, 6.0 μg, Diagenode PAb-003-050, previously used in
ChIP-seq studies [40,41]), and H3me3K9 (rabbit poly-
clonal, 3.0 μg, Abcam ab8898, previously used in ChIP-
chip studies [24,25]). The secondary rabbit anti-mouse IgG
was purchased from MP Biomedicals (Cat # 55436). Stand-
ard PCR reactions using 2 μL of the immunoprecipitated
DNA were performed to confirm the ChIP assay, followed
by standard electrophoresis procedures (1.5% agarose gels
and ethidium bromide visualization). Amplicons, prepared
using 50% to 80% of a ChIP sample, were generated using
Sigma’s Whole Genome Amplification Kit 2; see previously
published ChIP protocol (1) for details. Quality of the
amplicons was monitored by PCR of positive and negative
control regions. Re-amplification of the amplicons was pre-
pared using Genomeplex WGA Reamplification Kit
(WGA3, Sigma). We used the NimbleGen HD2 human
promoter microarray design, which focuses on human pro-
moters spanning 7 kb upstream and 3 kb downstream
around transcription start sites. The amplicons were sent
to NimbleGen Inc (Madison, WI) for application to the
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4115972,d.cGU). Briefly, 10 ug of Cy5-labeled ChIP DNA
and 10 ug of Cy3-labeled input DNA were applied to the
arrays. A complete description of this microarray design,
including the exact sequence for each spot on the array
and the associated data files, is available as part of the
GEO platform description for this microarray (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL9464).
Data Analysis
All analyses were with the hg18 genome assembly (see
UCSC genome browser: https://genome.ucsc.edu/) and
all specified coordinates reference this assembly unless
otherwise noted. All microarray data is available via
NCBI GEO (GSE60806). We employed a number of dif-
ferent analysis approaches to check the validity of our
conclusions. We used our previously developed software
[42] and custom software. All quoted values for array
amplitudes in this manuscript are in log2 enrichment
units, i.e. log2 (ChIP/input DNA). We began with the
full set of putative epigenetic sites as determined by the
standard NimbleGen analysis; this is the set indicated by
the term “generous parameters”. This set was used in all
analyses unless otherwise indicated (bivalent promoters
were defined differently - see below). To generate
these peaks, NimbleGen describes the procedure as
follows. The mean and standard deviation of the
probe distribution is calculated and a theoretical max-
imum is calculated as the mean plus six standard de-
viations. Peaks are then found by searching for at
least 4 probes within a 500 bp sliding window with
signals above specified cutoff values, ranging from
90% to 15% of the maximum. If a window has less
than 4 probes, then 3 probes are searched for and
then 2. The full set includes all peaks found by using
this procedure. Ratio data were randomized 20 times
to calculate the false discovery rate (FDR) for each






74115972,d.cGU. This full set enabled us to determine all
possible sites of modification within this microarray design.
We then mapped these peaks to proximal promoters using
the NimbleGen “5 kb” promoter array design for hg18 (see
[24]), which features promoters spanning 3.5 kb upstreamand 750 bp downstream. A promoter was considered posi-
tive for a modification if one or more NimbleGen peaks
overlapped the promoter. We used this promoter-centric
analysis for all data analyses except initial quantification of
peaks. We favored this approach primarily because epigen-
etic modifications in proximal promoter regions probably
have large effects on transcription. These regions are well
represented in this promoter-centric microarray design,
allowing us to accurately study this portion of the genome.
In addition, because this analysis method focuses on assign-
ing ~4 - 5 kb genomic regions (proximal promoters) to the
positive or negative sets as opposed to comparing exact
peak locations, it can obviate some subtle noise issues in
ChIP-chip work. For example, noise can affect the determin-
ation of the “width” and exact location of a given peak, mak-
ing detailed peak by peak analysis potentially very sensitive
to noise. By looking at larger genomic intervals as in prox-
imal promoters, we greatly reduce most issues surrounding
detailed analysis of peak widths and associated noise con-
cerns. We produced the “universe” set of promoters for a
given epigenetic mark by forming, for each epigenetic mark,
the union of positive promoters across BTSC types. In con-
trast, the core set represents, for each epigenetic mark, the
promoters that are positive for that mark in every BTSC
type. As an example, if a promoter is positive for H3K4me3
in only B12 cells and not in the other cell types, then it is in
the H3K4me3 universe set but not the core set. If a different
promoter is positive for H3K4me3 in all four BTSC types,
then it is in the H3K4me3 core set and the H3K4me3 uni-
verse set. We repeated all these basic analyses (generation of
positive promoters for each cell type/epigenetic mark com-
bination, “core” and “universe” set determination) using
peaks filtered so that they have FDR < 0.2 (datasets available
in Additional file 58). We found that use of this criterion
did not lead to significant changes in our overall conclusions
(see Additional file 1: Figures S8, S9). For determination of
bivalent promoters, we wished to use a more strict criterion
because we wanted a set that had strong signals for both
epigenetic modifications (either H3K4me3+/H3K27me3+ or
H3K4me3+/H3K9me3+). We began by using quantile
normalization (across arrays for the same epigenetic mark)
and then conservatively smoothing each array dataset using
a three point median smooth. Displayed data is generally
from this analysis procedure. We next remapped the data to
the “5 kb promoters” (as above) and applied maxfour, a
methodology used to score promoters for ChIP-chip [43]. In
brief, this approach scans each promoter region for the four
consecutive probes yielding the largest mean value, which is
the “maxfour value” for the promoter. We considered values
>1.0 (log2 enrichment, hence >2-fold) as showing enough
enrichment to indicate the presence of a peak in the pro-
moter and the promoter is scored as “maxfour positive” for
a factor under this condition. Hence, only promoters that
were both maxfour-positive and were scored as positive as
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conservative set. We verified our overall qualitative peak re-
sults (e.g. significant variability among BTSCs in sets of pro-
moters bearing a given epigenetic mark) by using other
analysis methods. In particular, we used various criteria as in
[25] to form a rank analysis of promoters and examine over-
lap in, for example, the top 2000 or top 4000 promoters as
determined by maxfour values. These analyses led to very
similar qualitative results as our standard analysis; for ex-
ample, BTSCs also showed large variability in sets of pro-
moters with a given epigenetic mark according to this
approach. For broad modification analyses, we examined
the 44 ENCODE regions [44] present in this array design
and examined each region for each of the four epigenetic
marks by eye. We operationally defined a broad modifica-
tion as >50 kb in length. Only regions that clearly displayed
extended broad peaks that differed among cell types were
considered to show a broad modification difference. For
quantification of overlap of peaks in bivalent promoters, we
wrote custom software. This software only analyzed pro-
moters for which the peak was entirely within the promoter,
so the numbers that could be analyzed were a subset of the
total. Refinement of this analysis is in process. For gene
categorization, we used the DAVID server using standard
parameters [26]. This resource not only uses gene ontology
categories in the standard analysis, but also uses other classi-
fications (e.g. “SP_PIR_KEYWORDS”); details are available
online (http://david.abcc.ncifcrf.gov/) and from [26].Isolation of RNA, Preparation of cDNA Library, and qPCR
BTSC and fNSC RNA were prepared using Trizol® Reagent
(Invitrogen). No DNase treatement was used. cDNA library
was generated using Omniscript RT Kit (QIAGEN) and
Oligo(dT)20 primer (Invitrogen) to a volume of 20 uL.
Typically 1 uL of this cDNA library was used per qPCR re-
action, with the same amount for every well in a given ex-
periment. qPCR was performed in triplicate with GAPDH
and ACTB as control genes for normalization using SYBR
green as a detector. All primer sets were confirmed to pro-
duce a single band product using conventional gel-PCR
and a single peak in melting curve analysis, which was per-
formed for every well at the conclusion of the experiment.
Experiments were performed using a BioRad CFX-96
qPCR instrument (Bio-Rad Inc., Hercules, CA, USA). Fur-
thermore, all primer sets were designed to produce a prod-
uct crossing exon-intron-exon boundaries, with the goal of
minimizing any effects from genomic DNA contamination.
Values are from simple delta-delta Ct analysis [45]. Primers
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